Alimera Sciences Announces Real-World Clinical Data for ILUVIEN® to be Presented at the American Academy of Ophthalmology 2020 Virtual Conference
November 12, 2020 08:00 ET
|
Alimera Sciences, Inc.
ATLANTA, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the...
Alimera Sciences Announces Third Quarter 2020 Financial Results
October 28, 2020 16:05 ET
|
Alimera Sciences, Inc.
Third Quarter Highlights: Consolidated Net Revenue of $12.5 Million Up 25% vs. Second Quarter 2020U.S. Net Revenue of $7.0 Million Up 106% vs. Second Quarter 2020Consolidated Net Revenue Down 3% vs....
Alimera Sciences to Report Third Quarter 2020 Financial Results on Wednesday, October 28, 2020 and Provide Corporate Update
October 22, 2020 08:00 ET
|
Alimera Sciences, Inc.
ATLANTA, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera” or the “Company”), a leader in the commercialization and development of prescription ophthalmology...
Alimera Sciences Announces Multiple Posters and Papers Highlighting the Durability of ILUVIEN® To Be Presented at the EURETINA 2020 Virtual Congress
September 23, 2020 08:00 ET
|
Alimera Sciences, Inc.
ATLANTA, Sept. 23, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the...
Alimera Sciences Signs Distribution Agreement With Medis Pharmaceutical to Commercialize Iluvien® in Austria and the Czech Republic
September 15, 2020 08:00 ET
|
Alimera Sciences, Inc.
ATLANTA, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the development and commercialization of prescription...
UPDATE -- Alimera Sciences Announces Participation at the H.C. Wainwright 22nd Annual Global Virtual Investment Conference on September 15, 2020
September 09, 2020 11:18 ET
|
Alimera Sciences, Inc.
ATLANTA, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the development and commercialization of prescription...
Alimera Sciences Announces Participation at the H.C. Wainwright 22nd Annual Global Virtual Investment Conference on September 15, 2020
September 09, 2020 08:00 ET
|
Alimera Sciences, Inc.
ATLANTA, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the development and commercialization of prescription...
Alimera Sciences Obtains Reimbursement Approval for ILUVIEN® Use in Non-Infectious Posterior Uveitis in Scotland
September 08, 2020 08:00 ET
|
Alimera Sciences, Inc.
ATLANTA, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the development and commercialization of prescription...
Alimera Sciences Announces Enrollment of First Patient in Landmark NEW DAY Clinical Trial to Evaluate ILUVIEN® as Baseline Therapy for Diabetic Macular Edema
September 01, 2020 08:00 ET
|
Alimera Sciences, Inc.
ATLANTA, Sept. 01, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company that specializes in the commercialization and development of prescription...
Alimera Sciences Announces National Reimbursement Granted for ILUVIEN® in the Netherlands
August 26, 2020 08:30 ET
|
Alimera Sciences, Inc.
ATLANTA, Aug. 26, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the development and commercialization of prescription...